Calyxt Inc (NASDAQ:CLXT) CEO James Blome sold 2,902 shares of Calyxt stock in a transaction on Monday, June 29th. The shares were sold at an average price of $5.01, for a total value of $14,539.02. Following the completion of the transaction, the chief executive officer now owns 198,057 shares of the company’s stock, valued at $992,265.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
James Blome also recently made the following trade(s):
- On Wednesday, July 1st, James Blome sold 3,495 shares of Calyxt stock. The shares were sold at an average price of $4.65, for a total value of $16,251.75.
Shares of CLXT stock opened at $4.41 on Friday. The company has a quick ratio of 8.80, a current ratio of 9.38 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $4.90 and a two-hundred day moving average price of $4.85. Calyxt Inc has a 12-month low of $2.40 and a 12-month high of $9.77.
Hedge funds have recently modified their holdings of the business. Oppenheimer & Co. Inc. bought a new stake in Calyxt during the first quarter worth about $47,000. Two Sigma Investments LP bought a new stake in shares of Calyxt in the 1st quarter valued at about $61,000. Bank of New York Mellon Corp lifted its stake in shares of Calyxt by 15.8% in the 1st quarter. Bank of New York Mellon Corp now owns 26,097 shares of the company’s stock valued at $86,000 after acquiring an additional 3,563 shares during the last quarter. UBS Group AG lifted its stake in shares of Calyxt by 40.4% in the 4th quarter. UBS Group AG now owns 14,296 shares of the company’s stock valued at $100,000 after acquiring an additional 4,116 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Calyxt by 26.9% in the 1st quarter. Wells Fargo & Company MN now owns 45,933 shares of the company’s stock valued at $153,000 after acquiring an additional 9,733 shares during the last quarter. 23.93% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts recently issued reports on the company. National Securities reissued a “buy” rating and set a $10.00 price objective on shares of Calyxt in a research note on Friday, May 8th. Wells Fargo & Co dropped their price objective on Calyxt from $6.00 to $4.00 and set an “equal weight” rating for the company in a research note on Friday, May 15th. Zacks Investment Research lowered Calyxt from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Canaccord Genuity assumed coverage on Calyxt in a research note on Tuesday, July 28th. They set a “buy” rating and a $8.00 price objective for the company. Finally, BMO Capital Markets lowered Calyxt from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $13.00 to $7.00 in a research note on Friday, May 8th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Calyxt presently has an average rating of “Hold” and an average price target of $6.88.
Calyxt Company Profile
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.
Featured Story: What is the return on assets formula?
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.